LADTX | Developing Growth Fund Class R5 | Lord Abbett

Tracked Funds

You have 0 funds on your mutual fund watch list.

Begin by selecting funds to create a personalized watch list.

(as of 12/05/2015)

Pending Orders

You have 0 items in your cart.

Subscribe and order forms, fact sheets, presentations, and other documents that can help advisers grow their business.

 

Developing Growth Fund

Track this Fund
Add to Hypo Tool

Summary

Summary

What is the Developing Growth Fund?

The Fund seeks to deliver long-term growth of capital by investing primarily in stocks of small U.S. companies.

Fund Basicsas of 10/31/2022

Total Net Assets
$2.67 B
Inception Date
06/30/2015
Dividend Frequency
Annually
Fund Expense Ratio
0.69%
Number of Holdings
92

Fund Expense Ratio :

0.69%

YTD 1-YR 3-YR 5-YR 10-YR Since Inception
w/o sales charge -31.67% -31.88% 5.40% 10.37% 11.95% -
Lipper Category Avg. Small-Cap Growth Funds -22.06% -20.43% 6.29% 7.54% 10.87% -
Russell 2000® Growth Index -21.31% -20.96% 3.68% 4.91% 10.24% -

Fund Expense Ratio :

0.69%

Fund Expense Ratio :

0.69%

YTD 1-YR 3-YR 5-YR 10-YR Since Inception
w/o sales charge -35.83% -37.94% 5.19% 10.20% 10.62% -
Lipper Category Avg. Small-Cap Growth Funds -30.15% -28.58% 4.76% 6.11% 9.44% -
Russell 2000® Growth Index -29.28% -29.27% 2.94% 3.60% 8.81% -

Fund Expense Ratio :

0.69%

TEN LARGEST HOLDINGS as of 10/31/2022View Portfolio

Holding Assets
Calix Inc 3.0%
Shockwave Medical Inc 2.2%
Chart Industries Inc 2.1%
Krystal Biotech Inc 2.1%
Lantheus Holdings Inc 2.1%
Livent Corp 2.1%
Cytokinetics Inc 2.0%
Karuna Therapeutics Inc 2.0%
Sarepta Therapeutics Inc 2.0%
HealthEquity Inc 1.9%

INVESTMENT TEAM

F. Thomas O'Halloran
F. Thomas O'Halloran, CFA, J.D.

Partner & Portfolio Manager

35 Years of Industry Experience

Matthew R. DeCicco
Matthew R. DeCicco, CFA

Partner & Director of Equities

21 Years of Industry Experience

Vernon Bice
Vernon Bice, CMT

Portfolio Manager

21 Years of Industry Experience

Benjamin Ebel
Benjamin Ebel

Portfolio Manager

30 Years of Industry Experience

Supported By 8 Investment Professionals with 18 Years Avg. Industry Experience

Your Representative

To contact your representative, enter your zip code and select your channel below.

Performance

Performance

Fund Expense Ratio :

0.69%

YTD 1-YR 3-YR 5-YR 10-YR Since Inception
w/o sales charge -31.67% -31.88% 5.40% 10.37% 11.95% -
Lipper Category Avg. Small-Cap Growth Funds -22.06% -20.43% 6.29% 7.54% 10.87% -
Russell 2000® Growth Index -21.31% -20.96% 3.68% 4.91% 10.24% -

Fund Expense Ratio :

0.69%

Fund Expense Ratio :

0.69%

YTD 1-YR 3-YR 5-YR 10-YR Since Inception
w/o sales charge -35.83% -37.94% 5.19% 10.20% 10.62% -
Lipper Category Avg. Small-Cap Growth Funds -30.15% -28.58% 4.76% 6.11% 9.44% -
Russell 2000® Growth Index -29.28% -29.27% 2.94% 3.60% 8.81% -

Fund Expense Ratio :

0.69%

Year Fund Returns Russell 2000® Growth Index
2021 -2.41% 2.83%
2020 72.95% 34.63%
2019 32.31% 28.48%
2018 5.32% -9.31%
2017 30.27% 22.17%
2016 -2.48% 11.32%
2015 -8.64% -1.38%
2014 3.56% 5.60%
2013 57.77% 43.30%
2012 10.73% 14.59%
2011 -1.30% -
2010 37.01% -
2009 47.54% -
2008 -47.31% -
2007 36.29% -
2006 12.86% -
2005 12.31% -
2004 6.39% -
Year Q1 Q2 Q3 Q4 Yearly Returns
2022 -19.22% -21.10% 0.68% - -35.60%
2021 1.72% 2.93% -3.63% -3.28% -2.41%
2020 -16.93% 40.77% 15.98% 27.53% 72.95%
2019 27.10% 9.18% -11.29% 7.48% 32.31%
2018 7.20% 15.07% 12.22% -23.91% 5.32%
2017 8.45% 4.10% 7.14% 7.71% 30.27%
2016 -10.24% 2.28% 10.94% -4.25% -2.48%
2015 7.18% 2.69% -15.63% -1.62% -8.64%
2014 1.76% 0.24% -5.71% 7.66% 3.56%
2013 13.60% 10.13% 18.88% 6.09% 57.77%
2012 12.24% -2.59% 5.66% -4.16% 10.73%
2011 10.32% 1.61% -20.78% 11.16% -1.30%
2010 8.25% -7.85% 16.61% 17.79% 37.01%
2009 -2.06% 24.50% 14.24% 5.91% 47.54%
2008 -21.75% 6.69% -11.69% -28.53% -47.31%
2007 4.75% 13.67% 9.96% 4.10% 36.29%
2006 16.07% -6.14% -6.74% 11.08% 12.86%
2005 -5.76% 5.86% 9.71% 2.62% 12.31%
2004 - - - 11.64% 6.39%

NAV Historical Prices

Date Net Asset Value

Portfolio

Portfolio

Portfolio Positioning as of 9/30/2022

  • The Fund is designed and managed to provide investors with access to the most innovative, high-growth companies in their respective industries. Our investment research process is iterative and continuous and includes three primary components: 1) identifying innovators and superior businesses, 2) assessing and quantifying operating momentum, and 3) assessing and quantifying stock price momentum
  • The inflationary environment has ushered in quantitative tightening and an increasingly hawkish Federal Reserve (the Fed), which has led to a challenging backdrop for innovation growth stocks. From a technical standpoint, most indicators continue to be weak with both market breadth and market sentiment trading at oversold levels. We continue to monitor supply and demand imbalances, inflationary pressures, and Fed policy. However, we have seen some positive signs over the last few months, such as earnings resiliency, a potential for peaking in food and commodity inflation, and technical strength in secular growth areas, such as biotechnology.
  • Accordingly, we continue to seek a reasonable balance of offensive and defensive stocks. Our offensive positioning consists largely of stocks that have sold off significantly and are now at the lower end of the market capitalization categories, while defensive positioning is mainly focused on areas that have healthy business conditions and constructive technical patterns, such as energy and pharmaceuticals.
  • Looking ahead into 2023 and beyond, our view continues to be that the powerful secular forces that kept inflation low before the pandemic - namely demographics, high debt levels, and the technology revolution - will reassert themselves at some point. Tighter monetary and fiscal policy, too, should cause inflation to decelerate from very high levels. However, until that happens, we are likely to continue to face a hostile Fed.
  • We remain bullish on the long-term outlook for equities because the technology revolution is ever more powerful with each passing year, providing a supportive backdrop for innovation in the Consumer, Communications, Healthcare, and Technology sectors in the decade ahead. We believe the opportunity set of terrific growth companies in these sectors at more reasonable valuations continues to expand. Many of these companies have dominant market positions, are experiencing tremendous growth, are very early on in their penetration, and have years of high compounding annual growth ahead, in our view.

Portfolio Details as of 10/31/2022

Total Net Assets
$2.67 B
Number of Holdings
92
Weighted Average Market Cap.
5.0 B
P/B Ratio
5.5x
P/E Ratio
23.3x

Contributors & Detractors as of  09/30/2022

Contributors

Holding Contribution
Shockwave Med Inc 1.0%
Calix Inc 0.9%
Livent Corp 0.5%
Axonics Modulation Tech 0.5%
Ameresco Inc 0.4%

Detractors

Holding Contribution
Intra-Cellular Therapies Inc -0.6%
Semtech Corp -0.4%
Sitime Corporation -0.4%
Alkermes plc -0.4%
Global E Online Ltd -0.3%

Attribution Analysis 

Developing Growth Fund Benchmark Variance
Sector Avg. Weight Base Return Avg. Weight Base Return Stock Selection Group Weight Total

Dividends & Cap Gains

Dividends & Cap Gains

Capital Gains Distributions

For
Record Date Reinvest & Payable Date Long-term Short-term * Total Reinvest Price
11/22/2021 11/23/2021 $3.3406 - $3.3406 $36.00

Upcoming Capital Gain Distribution

This section lists all anticipated Income and Capital Gain distribution dates and any actual distributions are subject to adequacy of earnings and must be approved by the Board of Directors/Trustees. Please note that dates are subject to change.

Fees & Expenses

Fees & Expenses

Expense Ratioas of 11/30/2022

0.69%

Fund Documents

Fund Documents

Download fund documents & literature, create email subscriptions, and place direct mail order

0Documents selected
Order
n/a
Portfolio Holdings 1Q
Publish Date:11/03/2015
n/a
Portfolio Holdings 3Q
Publish Date:11/03/2015
Summary Prospectus
Publish Date:11/03/2015
n/a
Statutory Prospectus
Publish Date:11/03/2015
SAI
Publish Date:11/03/2015
Annual Report
Publish Date:11/03/2015
Semi-Annual Report
Publish Date:11/03/2015
Fact Sheet
Publish Date:11/03/2015
Commentary
Publish Date:11/03/2015
Fund Story
Publish Date:11/03/2015

To order literature visit full website

You may add to your cart by selecting quantities in each row below.

No rows selected. Please Go back and select at least one fund document

 
Quantity
Quantity
Remove
Remove

The Russell 2000® Growth Index measures the performance of those Russell 2000 companies with higher price-to-book ratios and higher forecasted growth values.

Select funds to run a Morningstar Hypothetical Report.

    Please confirm your literature shipping address

    Please review the address information below and make any necessary changes.

    All literature orders will be shipped to the address that you enter below. This information can be edited at any time.

    Current Literature Shipping Address

    * Required field